Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Current Deferred Revenue: 2022-2024

Historic Current Deferred Revenue for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $6.0 million.

  • NewAmsterdam Pharma Co N.V's Current Deferred Revenue fell 62.67% to $3.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $3.0 million, marking a year-over-year decrease of 62.67%. This contributed to the annual value of $6.0 million for FY2024, which is 39.68% down from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Current Deferred Revenue stood at $6.0 million for FY2024, which was down 39.68% from $10.0 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Current Deferred Revenue peaked at $18.7 million during FY2022, and registered a low of $6.0 million during FY2024.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Current Deferred Revenue had a median value of $10.0 million in 2023 and averaged $11.5 million.
  • Data for NewAmsterdam Pharma Co N.V's Current Deferred Revenue shows a maximum YoY tumbled of 46.64% (in 2023) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Current Deferred Revenue (Yearly) stood at $18.7 million in 2022, then plummeted by 46.64% to $10.0 million in 2023, then slumped by 39.68% to $6.0 million in 2024.